Brief: Evelo Biosciences Provides Updated Guidance On Advancing Clinical Inflammation Programs

Evelo Biosciences

14/04/2022 12:11

April 14 (Reuters) - Evelo Biosciences Inc  EVLO.O :
    * EVELO BIOSCIENCES PROVIDES UPDATED GUIDANCE ON ADVANCING
CLINICAL INFLAMMATION PROGRAMS
    * EVELO BIOSCIENCES INC - GUIDANCE ON REGISTRATION TRIALS
FOR
EDP1815 IN PSORIASIS EXPECTED IN 3Q 2022
    * EVELO BIOSCIENCES INC - DATA FROM INITIAL COHORT OF
PATIENTS IN
PHASE 2 TRIAL OF EDP1815 IN ATOPIC DERMATITIS EXPECTED 1Q 2023
    * EVELO BIOSCIENCES INC - FASTER RELEASE CAPSULE COHORT TO
BE
ADDED TO ON-GOING PHASE 2 TRIAL OF EDP1815 IN ATOPIC DERMATITIS;
DATA EXPECTED 1H 2023
    * EVELO BIOSCIENCES INC - WILL PUT EDP1867 PROGRAM ON HOLD
FOLLOWING COMPLETION OF A PHASE 1 CLINICAL TRIAL

Source text for Eikon:  ID:nGNX8nG4Qr 
Further company coverage:  EVLO.O 

 ((reuters.briefs@thomsonreuters.com;))